Zobrazeno 1 - 10
of 20
pro vyhledávání: '"van Eerden RAG"'
Publikováno v:
International Journal of Nanomedicine, Vol Volume 15, Pp 8151-8166 (2020)
Ruben AG van Eerden,1 Ron HJ Mathijssen,1 Stijn LW Koolen1,2 1Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands; 2Department of Hospital Pharmacy, Erasmus MC University Medical Center, Rotterdam, the NetherlandsC
Externí odkaz:
https://doaj.org/article/da2b094e68184f01a02aca51e7ee3acb
Autor:
van der Kleij MBA; Department of Clinical Pharmacology, Division of Medical Oncology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek, Amsterdam, The Netherlands. m.vd.kleij@nki.nl.; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands. m.vd.kleij@nki.nl., Guchelaar NAD; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Meertens M; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek, Amsterdam, The Netherlands., Westerdijk K; Department of Medical Oncology, Research Institute for Medical Innovation, Radboud University Medical Centre, Nijmegen, The Netherlands., Giraud EL; Department of Pharmacy and Clinical Pharmacology, Research Institute for Medical Innovation, Radboud University Medical Centre, Nijmegen, The Netherlands., Bleckman RF; Department of Medical Oncology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands., Groenland SL; Department of Clinical Pharmacology, Division of Medical Oncology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek, Amsterdam, The Netherlands., van Eerden RAG; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Imholz ALT; Department of Medical Oncology, Deventer Hospital, Deventer, The Netherlands., Vulink AJE; Department of Medical Oncology, Reinier de Graaf Hospital, Delft, The Netherlands., Otten HM; Department of Medical Oncology, Meander Medical Centre, Amersfoort, The Netherlands., Fiebrich-Westra HB; Department of Medical Oncology, Isala Hospital, Zwolle, The Netherlands., Lubberman FJE; Department of Pharmacy, Gelderse Vallei Hospital, Ede, The Netherlands., Desar IME; Department of Medical Oncology, Research Institute for Medical Innovation, Radboud University Medical Centre, Nijmegen, The Netherlands., Moes DAR; Department of Clinical Pharmacy & Toxicology, Leiden University Medical Centre, Leiden, The Netherlands., Touw DJ; Department of Clinical Pharmacy and Pharmacology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands., Koolen SLW; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.; Department of Pharmacy, Erasmus University Medical Centre, Rotterdam, The Netherlands., Gelderblom H; Department of Medical Oncology, Leiden University Medical Centre, Leiden, The Netherlands., Reyners AKL; Department of Medical Oncology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands., van Erp NP; Department of Pharmacy and Clinical Pharmacology, Research Institute for Medical Innovation, Radboud University Medical Centre, Nijmegen, The Netherlands., Mathijssen RHJ; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Huitema ADR; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek, Amsterdam, The Netherlands.; Department of Clinical Pharmacy, Utrecht University Medical Centre, Utrecht, The Netherlands.; Department of Pharmacology, Princess Máxima Centre for Paediatric Oncology, Utrecht, The Netherlands., Steeghs N; Department of Clinical Pharmacology, Division of Medical Oncology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek, Amsterdam, The Netherlands.; Department of Medical Oncology, Utrecht University Medical Centre, Utrecht University, Utrecht, The Netherlands.
Publikováno v:
British journal of cancer [Br J Cancer] 2024 Sep; Vol. 131 (5), pp. 843-851. Date of Electronic Publication: 2024 Jul 06.
Autor:
Rietveld PCS; Department of Clinical Pharmacy, Erasmus MC, Rotterdam, the Netherlands; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands; Rotterdam Clinical Pharmacometrics Group, the Netherlands. Electronic address: p.rietveld@erasmusmc.nl., Guchelaar NAD; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., van Eerden RAG; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., de Boer NL; Department of Surgical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., de Bruijn P; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Sassen SDT; Department of Clinical Pharmacy, Erasmus MC, Rotterdam, the Netherlands; Rotterdam Clinical Pharmacometrics Group, the Netherlands., Madsen EVE; Department of Surgical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Koch BCP; Department of Clinical Pharmacy, Erasmus MC, Rotterdam, the Netherlands; Rotterdam Clinical Pharmacometrics Group, the Netherlands., Verhoef C; Department of Surgical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Burger JWA; Department of Surgery, Catharina Cancer Institute, Eindhoven, the Netherlands., Mathijssen RHJ; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Koolen SLW; Department of Clinical Pharmacy, Erasmus MC, Rotterdam, the Netherlands; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
Publikováno v:
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie [Biomed Pharmacother] 2024 Jul; Vol. 176, pp. 116820. Date of Electronic Publication: 2024 May 28.
Autor:
Rietveld PCS; Department of Clinical Pharmacy, Erasmus MC, Rotterdam, The Netherlands.; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.; Rotterdam Clinical Pharmacometrics Group, Rotterdam, The Netherlands., Sassen SDT; Department of Clinical Pharmacy, Erasmus MC, Rotterdam, The Netherlands.; Rotterdam Clinical Pharmacometrics Group, Rotterdam, The Netherlands., Guchelaar NAD; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., van Eerden RAG; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., de Boer NL; Department of Surgical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., van den Heuvel TBM; Department of Surgery, Catharina Hospital, Eindhoven, The Netherlands., Burger JWA; Department of Surgery, Catharina Hospital, Eindhoven, The Netherlands., Mathijssen RHJ; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Koch BCP; Department of Clinical Pharmacy, Erasmus MC, Rotterdam, The Netherlands.; Rotterdam Clinical Pharmacometrics Group, Rotterdam, The Netherlands., Koolen SLW; Department of Clinical Pharmacy, Erasmus MC, Rotterdam, The Netherlands.; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
Publikováno v:
CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2024 Jun; Vol. 13 (6), pp. 1006-1016. Date of Electronic Publication: 2024 Apr 17.
Autor:
van Eerden RAG; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., de Boer NL; Department of Surgical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., van Kooten JP; Department of Surgical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Bakkers C; Department of Surgery, Catharina Cancer Institute, Eindhoven, the Netherlands., Dietz MV; Department of Surgical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Creemers GM; Department of Medical Oncology, Catharina Cancer Institute, Eindhoven, the Netherlands., Buijs SM; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Bax R; Department of Medical Oncology, Catharina Cancer Institute, Eindhoven, the Netherlands., de Man FM; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Lurvink RJ; Department of Surgery, Catharina Cancer Institute, Eindhoven, the Netherlands., Diepeveen M; Department of Surgical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Brandt-Kerkhof ARM; Department of Surgical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., van Meerten E; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Koolen SLW; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.; Department of Hospital Pharmacy, Erasmus MC, Rotterdam, the Netherlands., de Hingh IHJT; Department of Surgery, Catharina Cancer Institute, Eindhoven, the Netherlands., Verhoef C; Department of Surgical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Mathijssen RHJ; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Burger JWA; Department of Surgery, Catharina Cancer Institute, Eindhoven, the Netherlands.
Publikováno v:
The British journal of surgery [Br J Surg] 2023 Oct 10; Vol. 110 (11), pp. 1502-1510.
Autor:
van Eerden RAG; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, PO box 2040, 3000 CA, Rotterdam, The Netherlands., IJzerman NS; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, PO box 2040, 3000 CA, Rotterdam, The Netherlands.; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., van Meekeren M; Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands., Oomen-de Hoop E; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, PO box 2040, 3000 CA, Rotterdam, The Netherlands., Guchelaar NAD; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, PO box 2040, 3000 CA, Rotterdam, The Netherlands., Visser AMW; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, PO box 2040, 3000 CA, Rotterdam, The Netherlands., Matic M; Department of Clinical Chemistry, Erasmus MC University Medical Center, Rotterdam, The Netherlands., van Schaik RHN; Department of Clinical Chemistry, Erasmus MC University Medical Center, Rotterdam, The Netherlands., de Bruijn P; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, PO box 2040, 3000 CA, Rotterdam, The Netherlands., Moes DAR; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands., Jobse PA; Department of Internal Medicine, ADRZ, Goes, The Netherlands., Gelderblom H; Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands., Huitema ADR; Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Pharmacology, Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.; Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands., Steeghs N; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Mathijssen RHJ; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, PO box 2040, 3000 CA, Rotterdam, The Netherlands., Koolen SLW; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, PO box 2040, 3000 CA, Rotterdam, The Netherlands. s.koolen@erasmusmc.nl.; Department of Pharmacy, Erasmus University Medical Center, Rotterdam, The Netherlands. s.koolen@erasmusmc.nl.
Publikováno v:
Clinical pharmacokinetics [Clin Pharmacokinet] 2023 Aug; Vol. 62 (8), pp. 1129-1139. Date of Electronic Publication: 2023 Jun 13.
Autor:
Groenland SL; Department of Clinical Pharmacology, Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. Electronic address: s.groenland@nki.nl., van Eerden RAG; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Westerdijk K; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands., Meertens M; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Koolen SLW; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands; Department of Pharmacy, Erasmus Medical Center, Rotterdam, The Netherlands., Moes DJAR; Department of Clinical Pharmacy & Toxicology, Leiden University Medical Center, Leiden, The Netherlands., de Vries N; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Rosing H; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Otten H; Department of Medical Oncology, Meander Medical Center, Amersfoort, The Netherlands., Vulink AJE; Department of Medical Oncology, Reinier de Graaf Hospital, Delft, The Netherlands., Desar IME; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands., Imholz ALT; Department of Medical Oncology, Deventer Hospital, Deventer, The Netherlands., Gelderblom H; Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands., van Erp NP; Department of Pharmacy, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands., Beijnen JH; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands., Mathijssen RHJ; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Huitema ADR; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands; Department of Pharmacology, Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands., Steeghs N; Department of Clinical Pharmacology, Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. Electronic address: n.steeghs@nki.nl.
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2022 Oct; Vol. 33 (10), pp. 1071-1082. Date of Electronic Publication: 2022 Jun 28.
Autor:
Guchelaar NAD; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands. Electronic address: n.guchelaar@erasmusmc.nl., van Eerden RAG; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Groenland SL; Department of Clinical Pharmacology, Division of Medical Oncology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands., Doorn LV; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Desar IME; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands., Eskens FALM; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Steeghs N; Department of Clinical Pharmacology, Division of Medical Oncology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands., van Erp NP; Department of Pharmacy, Radboud University Medical Center, Nijmegen, the Netherlands., Huitema ADR; Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands; Department of Pharmacy, Prinses Máxima Center for Pediatric Oncology, University Medical Center Utrecht, the Netherlands; Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht, the Netherlands., Mathijssen RHJ; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Koolen SLW; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands; Department of Pharmacy, Erasmus Medical Center, Rotterdam, the Netherlands.
Publikováno v:
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie [Biomed Pharmacother] 2022 Sep; Vol. 153, pp. 113393. Date of Electronic Publication: 2022 Jul 11.
Autor:
van Eerden RAG; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, Netherlands., van Doorn L; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, Netherlands., de Man FM; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, Netherlands., Heersche N; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, Netherlands., Doukas M; Department of Pathology, Erasmus University Medical Center Rotterdam, Rotterdam, Netherlands., van den Bosch TPP; Department of Pathology, Erasmus University Medical Center Rotterdam, Rotterdam, Netherlands., Oomen-de Hoop E; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, Netherlands., de Bruijn P; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, Netherlands., Bins S; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, Netherlands., Ibrahim E; Department of Pharmacy, Uppsala University, Uppsala, Sweden., Nikkessen S; Department of Gastroenterology and Hepatology Erasmus University Medical Center Rotterdam, Rotterdam, Netherlands., Friberg LE; Department of Pharmacy, Uppsala University, Uppsala, Sweden., Koolen SLW; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, Netherlands.; Department of Pharmacy, Erasmus University Medical Center Rotterdam, Rotterdam, Netherlands., Spaander MCW; Department of Gastroenterology and Hepatology Erasmus University Medical Center Rotterdam, Rotterdam, Netherlands., Mathijssen RHJ; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, Netherlands.
Publikováno v:
Frontiers in pharmacology [Front Pharmacol] 2021 Nov 11; Vol. 12, pp. 759146. Date of Electronic Publication: 2021 Nov 11 (Print Publication: 2021).
Autor:
Atrafi F; Department of Medical Oncology, Erasmus MC Cancer Institute, 3015 GD Rotterdam, The Netherlands., van Eerden RAG; Department of Medical Oncology, Erasmus MC Cancer Institute, 3015 GD Rotterdam, The Netherlands., Koolen SLW; Department of Medical Oncology, Erasmus MC Cancer Institute, 3015 GD Rotterdam, The Netherlands.; Department of Hospital Pharmacy, Erasmus MC, 3015 GD Rotterdam, The Netherlands., de Bruijn P; Department of Medical Oncology, Erasmus MC Cancer Institute, 3015 GD Rotterdam, The Netherlands., Rijcken CJF; Cristal Therapeutics, 6229 EV Maastricht, The Netherlands., Hanssen R; Cristal Therapeutics, 6229 EV Maastricht, The Netherlands., Eskens FALM; Department of Medical Oncology, Erasmus MC Cancer Institute, 3015 GD Rotterdam, The Netherlands., Lolkema MP; Department of Medical Oncology, Erasmus MC Cancer Institute, 3015 GD Rotterdam, The Netherlands., Oomen-de Hoop E; Department of Medical Oncology, Erasmus MC Cancer Institute, 3015 GD Rotterdam, The Netherlands., Damman J; Department of Pathology, Erasmus MC, 3015 GD Rotterdam, The Netherlands., Mathijssen RHJ; Department of Medical Oncology, Erasmus MC Cancer Institute, 3015 GD Rotterdam, The Netherlands.
Publikováno v:
Cancers [Cancers (Basel)] 2021 Jul 26; Vol. 13 (15). Date of Electronic Publication: 2021 Jul 26.